2025
SJR Q3
JCR Q4 · 1,4
25 matched articles
SCIE
Journal detail
Behavioural Pharmacology
- Publisher
- Lippincott Williams and Wilkins
- Country
- United States · Northern America
- Type
- journal
- ISSN
-
0955881014735849
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 0,444
- Quartile Q3
- H-Index 92
- Cites/doc 1,47
- Docs (3y) 146
- Cites (3y) 253
Clarivate
Web of Science · JCR · 2025
- JCR Q Q4
- JIF 1,4
- 5Y JIF 1,7
- JCI 0,47
WoS indexes
- SCIE
Subject classification
Categories (SJR)
- Pharmacology Q3
- Psychiatry and Mental Health Q3
Areas
- Medicine
- Pharmacology, Toxicology and Pharmaceutics
WoS categories
- Behavioral Sciences | Neurosciences | Pharmacology & Pharmacy
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q3 | Q4 | 0,444 | 1,4 | 1,7 | 0,47 | Q3 | 92 |
| 2024 | Q3 | Q4 | 0,523 | 1,6 | 1,8 | 0,51 | Q3 | 90 |
| 2023 | Q3 | Q3 | 0,455 | 1,6 | 1,9 | 0,51 | Q3 | 90 |
| 2022 | Q3 | Q4 | 0,49 | 1,6 | 1,9 | 0,52 | Q3 | 90 |
| 2021 | Q2 | Q4 | 0,588 | 2,3 | 2,4 | 0,56 | Q3 | 90 |
| 2020 | Q2 | Q3 | 0,711 | 2,3 | 2,2 | 0,57 | Q3 | 90 |
| 2019 | Q2 | Q4 | 0,592 | 1,7 | 1,9 | 0,53 | Q3 | 90 |
| 2018 | — | Q3 | — | 1,8 | 1,9 | 0,58 | Q3 | — |
| 2017 | Q2 | Q3 | 0,916 | 1,9 | 2,1 | 0,63 | Q3 | 90 |
| 2016 | Q2 | Q3 | 1,014 | 2,2 | 2,1 | — | — | 90 |
| 2015 | Q2 | Q3 | 0,881 | 2 | 2,1 | — | — | 90 |
| 2014 | Q1 | Q3 | 1,051 | 2,1 | 2,4 | — | — | 90 |
| 2013 | Q1 | Q3 | 1,125 | 2,2 | 2,5 | — | — | 90 |
| 2012 | Q1 | Q2 | 1,269 | 2,3 | 2,9 | — | — | 90 |
| 2011 | Q1 | Q2 | 1,313 | 2,7 | 3 | — | — | 90 |
| 2010 | Q1 | Q2 | 1,359 | 2,5 | 2,8 | — | — | 90 |
| 2009 | — | Q2 | — | 2,9 | 2,9 | — | — | — |
| 2008 | — | Q2 | — | 2,6 | 2,7 | — | — | — |
| 2007 | — | Q2 | — | 2,4 | 2,7 | — | — | — |
| 2006 | — | Q2 | — | 2,4 | — | — | — | — |
| 2005 | — | Q2 | — | 2,8 | — | — | — | — |
| 2004 | — | Q2 | — | 2,3 | — | — | — | — |
| 2003 | — | Q2 | — | 2,4 | — | — | — | — |
| 2002 | — | Q2 | — | 1,9 | — | — | — | — |
| 2001 | — | Q2 | — | 1,9 | — | — | — | — |
| 2000 | — | Q2 | — | 2,1 | — | — | — | — |
| 1999 | — | Q2 | — | 1,9 | — | — | — | — |
| 1998 | — | Q1 | — | 1,8 | — | — | — | — |
| 1997 | — | Q1 | — | 2,3 | — | — | — | — |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | BEHAVIORAL SCIENCES | SCIE | Q4 | Q4 | 46/57 |
| 2025 | NEUROSCIENCES | SCIE | Q4 | Q4 | 293/330 |
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q3 | 295/356 |
| 2024 | BEHAVIORAL SCIENCES | SCIE | Q4 | Q4 | 43/57 |
| 2024 | NEUROSCIENCES | SCIE | Q4 | Q4 | 262/314 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q3 | 265/352 |
| 2023 | BEHAVIORAL SCIENCES | SCIE | Q3 | Q4 | 39/55 |
| 2023 | NEUROSCIENCES | SCIE | Q4 | Q4 | 261/310 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 259/354 |
| 2022 | BEHAVIORAL SCIENCES | SCIE | Q4 | Q4 | 44/52 |
| 2022 | NEUROSCIENCES | SCIE | Q4 | Q4 | 248/272 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q3 | 242/278 |
| 2021 | BEHAVIORAL SCIENCES | SCIE | Q4 | Q4 | 40/53 |
| 2021 | NEUROSCIENCES | SCIE | Q4 | Q3 | 235/275 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q3 | 218/279 |
| 2020 | BEHAVIORAL SCIENCES | SCIE | Q3 | Q4 | 39/53 |
| 2020 | NEUROSCIENCES | SCIE | Q4 | Q4 | 218/273 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 207/276 |
| 2019 | BEHAVIORAL SCIENCES | SCIE | Q4 | Q4 | 41/53 |
| 2019 | NEUROSCIENCES | SCIE | Q4 | Q4 | 226/272 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q3 | 218/271 |
| 2018 | BEHAVIORAL SCIENCES | SCIE | Q4 | Q4 | 43/53 |
| 2018 | NEUROSCIENCES | SCIE | Q4 | Q3 | 221/267 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 197/267 |
| 2017 | BEHAVIORAL SCIENCES | SCIE | Q4 | Q4 | 39/51 |
| 2017 | NEUROSCIENCES | SCIE | Q4 | Q3 | 206/261 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 190/261 |
| 2016 | BEHAVIORAL SCIENCES | SCIE | Q3 | — | 33/51 |
| 2016 | NEUROSCIENCES | SCIE | Q3 | — | 177/259 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 148/257 |
| 2015 | BEHAVIORAL SCIENCES | SCIE | Q3 | — | 33/51 |
| 2015 | NEUROSCIENCES | SCIE | Q3 | — | 179/256 |
| 2015 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 155/255 |
| 2014 | BEHAVIORAL SCIENCES | SCIE | Q3 | — | 31/51 |
| 2014 | NEUROSCIENCES | SCIE | Q3 | — | 169/252 |
| 2014 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 138/255 |
| 2013 | BEHAVIORAL SCIENCES | SCIE | Q3 | — | 31/49 |
| 2013 | NEUROSCIENCES | SCIE | Q3 | — | 170/252 |
| 2013 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 132/256 |
| 2012 | BEHAVIORAL SCIENCES | SCIE | Q3 | — | 30/49 |
| 2012 | NEUROSCIENCES | SCIE | Q3 | — | 160/252 |
| 2012 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 123/261 |
| 2011 | BEHAVIORAL SCIENCES | SCIE | Q2 | — | 20/48 |
| 2011 | NEUROSCIENCES | SCIE | Q3 | — | 127/244 |
| 2011 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 96/261 |
| 2010 | BEHAVIORAL SCIENCES | SCIE | Q2 | — | 23/48 |
| 2010 | NEUROSCIENCES | SCIE | Q3 | — | 137/239 |
| 2010 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 109/252 |
| 2009 | BEHAVIORAL SCIENCES | SCIE | Q2 | — | 24/49 |
| 2009 | NEUROSCIENCES | SCIE | Q2 | — | 112/231 |
| 2009 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 83/237 |
| 2008 | BEHAVIORAL SCIENCES | SCIE | Q3 | — | 25/47 |
| 2008 | NEUROSCIENCES | SCIE | Q3 | — | 116/221 |
| 2008 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 90/219 |
| 2007 | BEHAVIORAL SCIENCES | SCIE | Q2 | — | 22/45 |
| 2007 | NEUROSCIENCES | SCIE | Q3 | — | 107/211 |
| 2007 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 82/205 |
| 2006 | BEHAVIORAL SCIENCES | SCIE | Q2 | — | 21/42 |
| 2006 | NEUROSCIENCES | SCIE | Q3 | — | 104/200 |
| 2006 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 80/199 |
| 2005 | BEHAVIORAL SCIENCES | SCIE | Q2 | — | 16/42 |
| 2005 | NEUROSCIENCES | SCIE | Q2 | — | 77/200 |
| 2005 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 52/193 |
| 2004 | BEHAVIORAL SCIENCES | SCIE | Q2 | — | 15/41 |
| 2004 | NEUROSCIENCES | SCIE | Q3 | — | 100/198 |
| 2004 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 62/187 |
| 2003 | BEHAVIORAL SCIENCES | SCIE | Q2 | — | 17/40 |
| 2003 | NEUROSCIENCES | SCIE | Q2 | — | 87/198 |
| 2003 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 54/185 |
| 2002 | BEHAVIORAL SCIENCES | SCIE | Q3 | — | 20/39 |
| 2002 | NEUROSCIENCES | SCIE | Q3 | — | 103/197 |
| 2002 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 67/188 |
| 2001 | BEHAVIORAL SCIENCES | SCIE | Q2 | — | 15/39 |
| 2001 | NEUROSCIENCES | SCIE | Q2 | — | 94/198 |
| 2001 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 57/186 |
| 2000 | BEHAVIORAL SCIENCES | SCIE | Q2 | — | 13/39 |
| 2000 | NEUROSCIENCES | SCIE | Q2 | — | 85/203 |
| 2000 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 47/181 |
| 1999 | BEHAVIORAL SCIENCES | SCIE | Q2 | — | 15/38 |
| 1999 | NEUROSCIENCES | SCIE | Q2 | — | 93/201 |
| 1999 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 52/175 |
| 1998 | BEHAVIORAL SCIENCES | SCIE | Q2 | — | 16/39 |
| 1998 | NEUROSCIENCES | SCIE | Q2 | — | 87/202 |
| 1998 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 42/178 |
| 1997 | BEHAVIORAL SCIENCES | SCIE | Q1 | — | 7/38 |
| 1997 | NEUROSCIENCES | SCIE | Q2 | — | 56/150 |
| 1997 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 27/157 |